Spots Global Cancer Trial Database for A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
Official Title: An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
Study ID: NCT03514407
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.
Detailed Description:
Eligibility
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Jonsson Comprehensive Cancer, Los Angeles, California, United States
Mayo Clinic Jacksonville - PPDS, Jacksonville, Florida, United States
Columbia University Medical Center, New York, New York, United States
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Istituto Ortopedico Rizzoli, Bologna, , Italy
Policlinico Sant'orsola-Malpighi, Bologna, , Italy
Ospedale Pediatrico Bambino Gesu IRCCS, Rome, , Italy
Hospital Universitario Vall d'Hebron, Barcelona, , Spain
Hospital Clínico San Carlos, Madrid, , Spain
The Christie NHS Foundation Trust, Manchester, , United Kingdom
Contact Details
Name: Fred Zheng, MD
Affiliation: Incyte Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
